Catalent acquires gene therapy specialist Paragon for $1.2bnDrug delivery technology provider Catalent is to acquire gene therapy company Paragon for $1.2 billion. Paragon specialises in Share XCatalent acquires gene therapy specialist Paragon for $1.2bnhttps://pharmaphorum.com/news/catalent-acquires-gene-therapy-paragon/
Oncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerWill it happen or not? There are doubts about whether the proposed $74 billion merger of cancer drug Share XOncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerhttps://pharmaphorum.com/views-analysis-oncology/oncology-round-up-shareholders-question-bms-celgene-merger-while-merck-cos-keytruda-keeps-getting-stronger/
Biogen buys UK gene therapy firm Nightstar for $800mBiogen has agreed to buy UK-based gene therapy biotech Nightstar, which focuses on using modified viruses as therapies Share XBiogen buys UK gene therapy firm Nightstar for $800mhttps://pharmaphorum.com/news/biogen-buys-uk-gene-therapy-firm-nightstar-for-800m/
Doubts over BMS-Celgene merger after Starboard interventionDoubts are mounting about whether Bristol-Myers Squibb’s $74 billion merger with Celgene will go ahead after another key Share XDoubts over BMS-Celgene merger after Starboard interventionhttps://pharmaphorum.com/news/doubts-over-bms-celgene-merger-after-starboard-intervention/
Largest BMS shareholder opposes Celgene dealBristol-Myers Squibb’s (BMS) largest shareholder has come out against the company’s planned merger with Celgene, putting the future Share XLargest BMS shareholder opposes Celgene dealhttps://pharmaphorum.com/news/largest-bms-shareholder-opposes-celgene-deal/
Ipsen to buy rare disease firm Clementia for up to $1.31bnFrance’s Ipsen has agreed to buy Canadian rare diseases biotech Clementia Pharmaceuticals in a deal worth up to Share XIpsen to buy rare disease firm Clementia for up to $1.31bnhttps://pharmaphorum.com/news/ipsen-to-buy-rare-disease-firm-clementia-for-up-to-1-31bn/
Roche to buy gene therapy firm Spark for $4.8 billionRoche is to buy gene therapy firm Spark Therapeutics for $4.8 billion, adding an already-approved treatment for inherited Share XRoche to buy gene therapy firm Spark for $4.8 billionhttps://pharmaphorum.com/news/roche-to-buy-spark-therapeutics/
Clinigen buys remaining rights to Novartis cancer drugUK pharma Clinigen is to buy the remaining rights to Novartis’ cancer drug Proleukin, in a deal worth Share XClinigen buys remaining rights to Novartis cancer drughttps://pharmaphorum.com/news/clinigen-buys-remaining-rights-to-novartis-cancer-drug/
Novartis spent $15bn on M&A last year, with more to comeThe comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last Share XNovartis spent $15bn on M&A last year, with more to comehttps://pharmaphorum.com/news/novartis-spent-15bn-on-ma-last-year-with-more-to-come/
